<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60067">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02323997</url>
  </required_header>
  <id_info>
    <org_study_id>CIN3+plus</org_study_id>
    <nct_id>NCT02323997</nct_id>
  </id_info>
  <brief_title>Human Papillomavirus in Cervical Cancer and Pre-cancer in Switzerland: The CIN3+Plus Study</brief_title>
  <acronym>CIN3+plus</acronym>
  <official_title>Human Papillomavirus‐Associated Cervical Neoplasia in Switzerland at the Start of a National Vaccination Programme: Crosssectional Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bern</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss Federal Office of Public Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Bern</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the types of HPV in samples from women with cervical pre-cancer
      and cancer and gather information to help investigate the impact of HPV vaccination in
      Switzerland.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Human papillomavirus presence and type</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">767</enrollment>
  <condition>Cervical Cancer</condition>
  <biospec_descr>
    <textblock>
      Histologically confirmed CIN3+ lesions, i.e. CIN3, adenocarcinoma in situ and invasive
      carcinoma of the cervix.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Women with histologically confirmed CIN3+ lesions
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant is willing and able to give informed consent for participation in the
             study.

          -  Participant is literate in German, French, Italian or English.

          -  Female, aged 18 years or above.

          -  Histologically confirmed CIN3+ lesions, i.e. CIN3, adenocarcinoma in situ and
             invasive carcinoma of the cervix.

          -  Participant resides in the canton Zurich, Geneva, Basel, Baselland, Luzern or Ticino.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicola Low</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bern, Institute of Social and Preventive Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Viollier AG</name>
      <address>
        <city>Allschwil</city>
        <state>Baselland</state>
        <zip>4123</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Basel</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Viollier Weintraub SA</name>
      <address>
        <city>Geneva</city>
        <zip>1206</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HUG ‐ Hôpitaux Universitaires de Genève</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Baselland</name>
      <address>
        <city>Liestal</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto cantonale di patologia</name>
      <address>
        <city>Locarno</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Luzern</name>
      <address>
        <city>Luzern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Pathology Enge</name>
      <address>
        <city>Zurich</city>
        <zip>8002</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut für klinische Pathologie Medica</name>
      <address>
        <city>Zurich</city>
        <zip>8024</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Zürich</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 25, 2016</lastchanged_date>
  <firstreceived_date>December 18, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HPV</keyword>
  <keyword>cervical cancer</keyword>
  <keyword>human papillomavirus</keyword>
  <keyword>cervical pre-cancer</keyword>
  <keyword>cervical neoplasia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
